Press Releases.

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.

VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update

VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update

VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar